Neurocrine Biosciences, Inc. (NBIX)
127.75
-1.14
(-0.88%)
USD |
NASDAQ |
Apr 13, 10:58
Neurocrine Biosciences Enterprise Value : 11.93B for April 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Soleno Therapeutics, Inc. | 2.464B |
| Glaukos Corp. | 6.588B |
| Edgewise Therapeutics, Inc. | 2.994B |
| Nuvalent, Inc. | 6.705B |
| Biogen, Inc. | 28.23B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 153.70M |
| Revenue (Quarterly) | 805.50M |
| Total Expenses (Quarterly) | 651.80M |
| EPS Diluted (Quarterly) | 1.482 |
| Gross Profit Margin (Quarterly) | 97.82% |
| Profit Margin (Quarterly) | 19.08% |
| Earnings Yield | 3.65% |
| Operating Earnings Yield | 4.86% |
| Normalized Earnings Yield | 3.768 |